A biotech start-up using nanotechnology for regenerative medicine, advanced therapies, drug discovery and 3D organoid cell culture, with an extensive patent portfolio. MICA is currently seeking Series A Venture investment to supercharge its clinical trials. MICA Biosystems holds a diverse product/ therapy portfolio, reflecting an extensive R&D effort since its inception and founding by world-class researchers in the fields of biotechnology, cell engineering, regenerative medicine and bioengineering. The 3 main offerings, at differing stages of market approach, are listed below: ▸ MICA Cell Therapy; We use nanoparticles and an induced magnetic field to actively and accurately control the differentiation of stem cells in vivo in a highly location-specific, minimally-invasive procedure. MICA is currently pursuing clinical trials in Spinal Repair after successful preclinical trials in mammals, using this technology to aid in spinal fusion. ▸ Dynascreen™; The purpose of in vitro testing in drug screening is to mimic the in vivo environment as closely as possible. However, the majority of industry-standard tests are done in a static, unmoving environment where cells are not subjected to any mechanical forces, which does not reflect any in vivo environment. Dynascreen™ provides mechanical stimulation to cells in an assay as a bolt-on addition to existing instrumentation and methodologies. This low-cost, low-impact solution can be applied to a range of assays and is not cell-line specific, with incredible peer-reviewed data to prove its efficacy. ▸ MICA Bioreactor; We use a nanotechnology and magnetic forces to provide mechanical stimulation to cell cultures, facilitating 3D structure and organoid cell cultures, using our patented instrumentation.